PolyPid (@PolyPidLtd) header
PolyPid (@PolyPidLtd) profile picture

PolyPid

@PolyPidLtd

We are PolyPid! A late-stage biopharmaceutical company aiming to improve surgical outcomes. $PYPD #RightWhereCareBegins

polypid.com/
Joined December 2020
  • Tweets316
  • Following125
  • Followers369
174Media
Photo by PolyPid (@PolyPidLtd)Photo by PolyPid (@PolyPidLtd)Photo by PolyPid (@PolyPidLtd)Photo by PolyPid (@PolyPidLtd)Photo by PolyPid (@PolyPidLtd)Photo by PolyPid (@PolyPidLtd)Photo by PolyPid (@PolyPidLtd)Photo by PolyPid (@PolyPidLtd)Photo by PolyPid (@PolyPidLtd)Photo by PolyPid (@PolyPidLtd)
$PYPD Q3 2026 results on Wed., Nov. 11, before the U.S. market open. Call and webcast at 8:30 AM ET.
Image from PolyPid (@PolyPidLtd)
1
2
7
415
Details and call registration: globenewswire.com/news-relea…
PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11,...

PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11,...

PETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company...

globenewswire.com
38
$PYPD 2030 Investor Day Recap: New candidate PD01B for diabetic foot infections: pre-IND meeting and first-in-human expected 2H 2027. D-PLEX₁₀₀ PDUFA on track for Nov 28, 2026; U.S. launch expected 2027, subject to FDA approval; EMA decision 2H 2027.
1
2
2
8
546
Watch the Replay: vimeo.com/1240660247
PolyPid 2030 Investor Day and KOL event - October 2026

PolyPid 2030 Investor Day and KOL event - October 2026

In this Event PolyPid unveiled its expanded pipeline strategy, extending its Kynatrix delivery technology from infection prevention to infection treatment, beginning with PD01B. The Company discusses...

vimeo.com
1
61
$PYPD PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for Diabetic Foot Infections. Read the full release: globenewswire.com/news-relea…
Image from PolyPid (@PolyPidLtd)
1
6
197
Virtual Investor Day today at 11:30 a.m. ET with Warren Joseph, DPM, FIDSA. Join the webcast: edge.media-server.com/mmc/p/…
51
$PYPD Reminder: Join PolyPid 2030: Virtual Investor Day & KOL Event this Wednesday, Oct 28 at 11:30 a.m. ET. Pipeline strategy, D-PLEX₁₀₀ update, introducing PD01B, plus live Q&A with Warren Joseph, DPM, FIDSA. Watch live: edge.media-server.com/mmc/p/…
Image from PolyPid (@PolyPidLtd)
1
5
333
$PYPD PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026 investors.polypid.com/news-r…
Image from PolyPid (@PolyPidLtd)
3
193
$PYPD Today we announced two important updates that we believe further strengthen the path forward for D-PLEX₁₀₀ in Europe. 🧵 1/4
Image from PolyPid (@PolyPidLtd)
1
1
2
8
2,479
more replies
PolyPid also announced that it has regained exclusive European commercialization rights for D-PLEX₁₀₀ from ADVANZ PHARMA, expanding its strategic flexibility as it advances toward potential commercialization. >> investors.polypid.com/news-r… $PYPD 3/4 ⬇️

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀ |...

PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month Validation confirms that the application is complete and EMA initiates formal review of...

investors.polypid.com
1
1
194
Together, we believe these developments represent meaningful progress for PolyPid as it continues advancing D-PLEX₁₀₀ across major global markets. $PYPD 4/4
2
146
$PYPD PolyPid Announces Participation in Upcoming Fall Investor Conferences Read the Full News Release 👉 globenewswire.com/news-relea…
Image from PolyPid (@PolyPidLtd)
8
499
$PYPD update: I spoke with Polypid’s Ori Warshavsky about D-PLEX 100, FDA Priority Review, the Nov. 28 PDUFA target date, and the Azurity partnership. Up to $320M in milestones, royalties, manufacturing margin, and a hospital-focused launch strategy. Full interview: youtu.be/VfeI7Rm5kvs Not investment advice.
Polypid may be one of the most misunderstood small-cap biotech...

Polypid may be one of the most misunderstood small-cap biotech...

In this follow-up interview, Tim Weintraut of Alpha Wolf Capital si...

youtube.com
2
1
12
2,822
$PYPD PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 Read the Full News Release 👉 globenewswire.com/news-relea…
Image from PolyPid (@PolyPidLtd)
4
386
$PYPD PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀ Read the Full Press Release 👉 globenewswire.com/news-relea…
Image from PolyPid (@PolyPidLtd)
1
1
1
12
807
$PYPD Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada. Read full announcement: investors.polypid.com/news-r…
1
2
1
13
3,567
$PYPD PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀ Read the Full Press Release 👉 globenewswire.com/news-relea…
Image from PolyPid (@PolyPidLtd)
2
7
742
$PYPD PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference Read the Full News Release 👉 globenewswire.com/news-relea…
Image from PolyPid (@PolyPidLtd)
3
420
Key highlights from $PYPD Q1 2026 call: ⚡ U.S. Commercial Partnership Discussions in Late Stages ⚡ Initiated NDA Submission to the FDA under Rolling Review ⚡ Advancing EU Regulatory Submission Full PR here: bit.ly/42t3mBt
Image from PolyPid (@PolyPidLtd)
1
7
2,389
Load more